Mayzent Archives -

NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s

Consternation as NICE rejects Janssen MS drug Ponvory

https://pharmaphorum.com/news/consternation-as-nice-rejects-janssen-ms-drug-ponvory/

UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down

NICE changes its mind on Novartis’ progressive MS drug Mayzent

https://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-progressive-ms-drug-mayzent/

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the

NICE says no to Novartis’ Mayzent in secondary progressive MS

https://pharmaphorum.com/news/nice-says-no-to-novartis-mayzent-in-secondary-progressive-ms/

The EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvals

https://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/

Mayzent